Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer
Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer
复制标题
DOI：
10.1136/gut.2008.162883
复制
发表时间：
2009-04-01
期刊：
影响因子：
24.5
通讯作者：
Fraser, C. G.
中科院分区：
文献类型：
--
作者：
Steele, R. J. C.;McClements, P. L.;Fraser, C. G.
目标：评估基于愈创木脂粪便潜血检测 (gFOBT) 的前三轮结直肠筛查试点计划的效果及其对全国人口计划的影响。方法：在三个苏格兰 NHS 委员会进行了一项示范试点计划。研究纳入了社区健康指数登记的50岁至69岁居民。结果：第一轮的摄取率为55.0%，阳性率为2.07%，癌症检出率为2.1/1000人筛查。第二轮分别为53.0%、1.90%和1.2/1000，第三轮分别为55.3%、1.16%和0.7/1000。在第一轮中，gFOBT对于癌症的阳性预测值为12.0%，对于腺瘤的阳性预测值为36.5%；第二轮下降至7.0%和30.3%，第三轮则维持在7.5%和29.1%。杜克斯 A 期筛查检测出癌症的百分比在第一轮中为 49.2%，在第二轮中为 40.1%，在第三轮中为 36.3%。结论：这些结果与之前在研究环境中进行的随机试验的结果一致，表明基于人群的结直肠癌筛查在苏格兰是可行的，并且应该会导致疾病特异性死亡率的相应降低。
Objectives: To assess the effects of the first three rounds of a pilot colorectal screening programme based on guaiac faecal occult blood testing (gFOBT) and their implications for a national population-based programme.Methods: A demonstration pilot programme was conducted in three Scottish NHS Boards. Residents aged between 50 and 69 years registered on the Community Health Index were included in the study.Results: In the first round, the uptake was 55.0%, the positivity rate was 2.07% and the cancer detection rate was 2.1/1000 screened. In the second round, these were 53.0%, 1.90% and 1.2/1000, respectively, and in the third round, 55.3%, 1.16% and 0.7/1000, respectively. In the first round, the positive predictive value of the gFOBT was 12.0% for cancer and 36.5% for adenoma; these fell to 7.0% and 30.3% in the second round and were maintained at 7.5% and 29.1% in the third round. The percentage of screen-detected cancers diagnosed at Dukes' stage A was 49.2% in the first round, 40.1% in the second round and 36.3% in the third round.Conclusions: These results are compatible with those of previous randomised trials done in research settings, demonstrating that population-based colorectal cancer screening is feasible in Scotland and should lead to a comparable reduction in disease-specific mortality.